First Wave BioPharma Inc
NASDAQ:ENTO

Watchlist Manager
First Wave BioPharma Inc Logo
First Wave BioPharma Inc
NASDAQ:ENTO
Watchlist
Price: 2.55 USD -3.04% Market Closed
Market Cap: 8.6m USD

Intrinsic Value

The intrinsic value of one ENTO stock under the Base Case scenario is 0.05 USD. Compared to the current market price of 2.55 USD, First Wave BioPharma Inc is Overvalued by 98%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ENTO Intrinsic Value
0.05 USD
Overvaluation 98%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
First Wave BioPharma Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ENTO?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ENTO valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for First Wave BioPharma Inc.

Explain Valuation
Compare ENTO to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ENTO?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
First Wave BioPharma Inc

Balance Sheet Decomposition
First Wave BioPharma Inc

Current Assets 83.3m
Cash & Short-Term Investments 4.5k
Other Current Assets 83.3m
Non-Current Assets 1.7m
Intangibles 1.7m
Other Non-Current Assets 56.2k
Current Liabilities 29.7m
Accounts Payable 3.3m
Accrued Liabilities 551.1k
Short-Term Debt 700k
Other Current Liabilities 25.1m
Efficiency

Free Cash Flow Analysis
First Wave BioPharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
First Wave BioPharma Inc

Revenue
0 USD
Operating Expenses
-4.7m USD
Operating Income
-4.7m USD
Other Expenses
-12.8m USD
Net Income
-17.4m USD
Fundamental Scores

ENTO Profitability Score
Profitability Due Diligence

First Wave BioPharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Negative ROE
26/100
Profitability
Score

First Wave BioPharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

ENTO Solvency Score
Solvency Due Diligence

First Wave BioPharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Positive Net Debt
37/100
Solvency
Score

First Wave BioPharma Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ENTO Price Targets Summary
First Wave BioPharma Inc

There are no price targets for ENTO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

First Wave BioPharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ENTO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ENTO Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ENTO stock?

The intrinsic value of one ENTO stock under the Base Case scenario is 0.05 USD.

Is ENTO stock undervalued or overvalued?

Compared to the current market price of 2.55 USD, First Wave BioPharma Inc is Overvalued by 98%.

Back to Top